Tesamorelin
Tesamorelin Acetate
FDA-approved GHRH analog that reduces visceral fat
Tesamorelin is an FDA-approved GHRH analog specifically indicated for reducing visceral adipose tissue. One of the few peptides with current regulatory approval.
Admin routes
Subcutaneous
Popularity
Medium
Side effects
Generally mild
AU vendors
0 rated
✓Key benefits
📈What to expect
GH and IGF-1 levels begin rising
Subtle visceral fat reduction measurable on scans
Significant trunk fat reduction in clinical data
Maximum visceral fat reduction achieved in trials
Based on community reports and published research. Individual results vary significantly.
💊Dosing protocols
Visceral fat reduction
2 mg
Once daily
3–6 months minimum
GH optimisation
1–2 mg
Once daily before bed
3–6 months
Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.
Research status|FDA-approved (Egrifta, 2010) - extensive Phase 3 data
Overview
Tesamorelin is a synthetic GHRH analog approved by the FDA in 2010 (brand name Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It stimulates GH release from the pituitary similarly to sermorelin but with greater potency and a longer half-life due to the addition of a trans-3-hexenoic acid group. Off-label, it is widely used in longevity medicine for visceral fat reduction and GH optimisation.
⚙️How it works
Binds to GHRH receptors on the anterior pituitary, stimulating natural GH release. The trans-3-hexenoic acid modification increases resistance to enzymatic degradation (DPP-IV), extending its duration of action. Like sermorelin, it preserves the body's natural GH feedback mechanisms. Clinical trials showed significant reductions in trunk fat (visceral adipose tissue) without affecting subcutaneous fat or glucose tolerance.
⚡Side effects
📅Research history
Phase 2 trials by Theratechnologies demonstrate visceral fat reduction
Phase 3 JAMA publication confirms efficacy
FDA approves Egrifta for HIV-associated lipodystrophy
Further studies show liver fat reduction benefits
Off-label adoption in longevity and anti-aging clinics
Tesamorelin vs sermorelin
Both are GHRH analogs that stimulate natural GH production. Tesamorelin is more potent, has FDA approval (stronger safety data), and has been specifically proven to reduce visceral fat in clinical trials. Sermorelin is less potent but cheaper and more widely available through compounders. For visceral fat reduction specifically, tesamorelin has the stronger evidence base.
References
- [1]Falutz J, et al. 'Effects of tesamorelin on body composition and metabolic parameters.' JAMA, 2007.
- [2]Stanley TL, et al. 'Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients.' JAMA, 2014.
Frequently asked questions
Related peptides
Sermorelin
Growth HormoneThe original GH-releasing peptide - FDA-approved since 1997
0 rated vendors
CJC-1295 + Ipamorelin
Growth HormoneThe growth hormone secretagogue stack that works while you sleep
5 rated vendors
AOD-9604
Weight ManagementThe HGH fragment that targets fat without the side effects
4 rated vendors
Community experiences
Share your experience with Tesamorelin. Effects, side effects, protocol details - help others make informed decisions.
No community reviews yet. Be the first to share your experience with Tesamorelin.
Need to calculate your dose?
Use our free reconstitution calculator to work out syringe units for Tesamorelin.
Open CalculatorDisclaimer: This guide is for educational and informational purposes only. It is not medical advice. The dosing protocols listed are sourced from published research and community reports and do not constitute a recommendation. Always consult a qualified healthcare professional before using any peptide. Australian regulations classify many peptides as Schedule 4 (prescription-only) substances. Check current TGA guidelines before purchasing.